# Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

> **NCT04166565** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting European Myeloma Network** · enrollment: 41 (actual)

## Conditions studied

- Multiple Myeloma
- Extramedullary Plasmacytoma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04166565
- **Lead sponsor:** Stichting European Myeloma Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-31
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166565, "Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04166565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*